2. Signaling Pathways
  3. GPCR/G Protein
  4. GLP Receptor

GLP Receptor

GLP Receptor

The GLP receptors contain two family members, GLP-1 receptor (GLP1R, or GLP-1R) and GLP-2 receptor (GLP2R or GLP-1R), activated by the glucagon-like peptides (GLPs). GLPs are s secreted by intestinal cells; causes insulin release; inhibits glucagon secretion, appetite, and energy intake; and delays gastric emptying because GLP receptors are located on the gut, pancreas, brainstem, hypothalamus, and vagal-afferent nerves. GLP-1 has only one known receptor, GLP1R, and regulates gut motility, appetite, islet function, and glucose homeostasis, whereas GLP-2, the agonist of GLP2R, enhances intestinal nutrient absorption. GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome. An investigation of the actions of GLP receptor activation on gallbladder motility has demonstrated that GLP-2 receptor activation increases gallbladder volume in vivo and decreases spontaneous activity in GBSM bundles ex vivo. Like the inhibitory transmitters, which elicit their actions via an adenylate cyclase-protein kinase A-KATP channel pathway, the GLP-2 receptor signals through this same pathway.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P10910
    Vensemaglutide
    		Agonist
    Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders.
    Vensemaglutide
  • HY-P0165B
    Taspoglutide acetate
    		Agonist
    Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model.
    Taspoglutide acetate
  • HY-172410
    GLP-1R agonist 28
    		Agonist
    GLP-1R agonist 28 (Compound 19) is an orally active GLP-1R agonist. GLP-1R agonist 28 can increase insulin secretion and can be used in the research of GLP-1R-related diseases.
    GLP-1R agonist 28
  • HY-P1543
    Exendin-3
    		Antagonist 98.31%
    Exendin-3 is a biologically active peptides isolated from venoms of the Gila monster lizards, Heloderma horridurn.
    Exendin-3
  • HY-153193
    LSN3160440
    		Modulator
    LSN3160440 is an allosteric modulator of GLP-1R, which acts as a protein–protein interaction (PPI) stabilizer or molecular glue to assist in the adhesion of inactive GLP-1 (9-36) NH2 on GLP-1R.
    LSN3160440
  • HY-P10842
    d-GLP-2 E33A
    		Agonist
    d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC50 of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases.
    d-GLP-2 E33A
  • HY-162434
    I-128
    		Agonist
    I-128 is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0122 nM.
    I-128
  • HY-161915
    GLP-1R agonist 23
    		Agonist
    GLP-1R agonist 23 (Example 376) is a GLP-1R agonist with an EC50 of 0.056 nM. GLP-1R agonist 23 can be used in diabetes research.
    GLP-1R agonist 23
  • HY-147626
    GLP-1R agonist 13
    		Agonist
    GLP-1R agonist 13 (Compound 24) is a GLP-1 receptor agonist.
    GLP-1R agonist 13
  • HY-P10271
    RG7697
    		Agonist
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property.
    RG7697
  • HY-P4389
    (Asp28)-Glucagon (1-29) (human, rat, porcine)
    		Activator
    (Asp28)-Glucagon (1-29) (human, rat, porcine) is an optimized structure of glucagon, the 28th position is replaced by aspartic acid (Asp) which significantly increases the aqueous solubility of glucagon in a physiological pH buffer, has the same activity as glucagon.
    (Asp28)-Glucagon (1-29) (human, rat, porcine)
  • HY-170516
    GLP-1 receptor agonist 16
    		Agonist
    GLP-1 receptor agonist 16 (Example 53) is a GLP-1 agonist. GLP-1 receptor agonist 16 can be used for the research of diabetes, obesity, or nonalcoholic steatohepatitis-related diseases[1].
    GLP-1 receptor agonist 16
  • HY-P10312
    SPN009
    		Agonist
    SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models.
    SPN009
  • HY-162979
    GLP-1R agonist 25
    		Agonist
    GLP-1R agonist 25 (compound 13) is a GLP1-R agonist, with an EC50 of 0.167 nM. GLP-1R agonist 25 can be used in type II diabetes research.
    GLP-1R agonist 25
  • HY-P10337
    OXM-7
    		Agonist
    OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism.
    OXM-7
  • HY-P4841
    GLP-1 (7-36)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat)
    GLP-1 (7-36)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat) is a biotinylated GLP-1 fragment, corresponding to the 7-36 sequence of GLP-1.
    GLP-1 (7-36)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat)
  • HY-W823500
    GLP-1 Receptor modulator 1
    GLP-1 Receptor modulator 1 (Compound 7) is a potent GLP-1 receptor positive allosteric modulator. GLP-1 Receptor modulator 1 can be used for the research of obesity and type 2 diabetes.
    GLP-1 Receptor modulator 1
  • HY-P0014AS
    Liraglutide-d8 tetraTFA
    		Agonist
    Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
    Liraglutide-d8 tetraTFA
  • HY-168585
    GLP-1R agonist 26
    		Agonist
    GLP-1R agonist 26 (compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of <10 nM.
    GLP-1R agonist 26
  • HY-172411
    GLP-1R agonist 29
    		Agonist
    GLP-1R agonist 29 (Compound 20) is the agonist for GLP-1R that induces hGLP-1R mediated cAMP stimulation with an EC50 of 0.018 nM. GLP-1R agonist 29 exhibits good pharmacokinetics characteristics with good body exposure of AUC0-∞,sc of 77688 ng·h/mL.
    GLP-1R agonist 29
Cat. No. Product Name / Synonyms Application Reactivity